PepGen Inc
PEPG1.880USD
-0.170-8.29%
收盘 09/19, 16:00（美东）报价延迟15分钟
61.66M总市值
亏损市盈率 TTM
关于 PepGen Inc 公司
PepGen Inc. 是一家临床阶段的生物技术公司。该公司致力于推进下一代寡核苷酸疗法，旨在改变严重神经肌肉和神经系统疾病的治疗方法。其专有的增强递送寡核苷酸 (EDO) 平台利用细胞穿透肽来改善结合寡核苷酸疗法的吸收和活性。其 EDO 肽经过精心设计，可优化组织渗透、细胞吸收和核递送。利用这些 EDO 肽，该公司正在生成一系列寡核苷酸治疗候选药物，旨在针对严重疾病的根本原因。该公司的管线包括两个临床阶段项目：用于适合外显子 51 跳跃的杜氏肌营养不良症 (DMD) 患者的 PGN-EDO51 和用于 1 型肌强直性营养不良症 (DM1) 患者的 PGN-EDODM1。它还有另外三个临床前阶段项目：PGN-EDO53、PGN-EDO45 和 PGN-EDO44。
公司简介
公司代码PEPG
公司名称PepGen Inc
上市日期May 06, 2022
CEODr. James G. Mcarthur, Ph.D.
员工数量81
证券类型Ordinary Share
年结日May 06
公司地址245 Main St, 2nd Floor
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02142
电话17034568000
网址https://pepgen.com
公司代码PEPG
上市日期May 06, 2022
CEODr. James G. Mcarthur, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+3040.14%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
1.43K
-8.67%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Dr. Howard Mayer, M.D.
Dr. Howard Mayer, M.D.
Independent Director
Independent Director
--
--
Dr. Kasra Kasraian, Ph.D.
Dr. Kasra Kasraian, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+3040.14%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
1.43K
-8.67%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
32.59%
Oxford Science Enterprises PLC
14.50%
Point72 Asset Management, L.P.
8.41%
Millennium Management LLC
4.60%
Viking Global Investors LP
4.52%
其他
35.38%
持股股东
持股股东
占比
RA Capital Management, LP
32.59%
Oxford Science Enterprises PLC
14.50%
Point72 Asset Management, L.P.
8.41%
Millennium Management LLC
4.60%
Viking Global Investors LP
4.52%
其他
35.38%
股东类型
持股股东
占比
Venture Capital
47.09%
Hedge Fund
26.11%
Investment Advisor/Hedge Fund
6.31%
Investment Advisor
5.65%
Sovereign Wealth Fund
3.79%
Research Firm
0.53%
Individual Investor
0.27%
其他
10.24%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
165
31.28M
95.59%
-5.47M
2025Q1
168
31.44M
96.09%
-5.26M
2024Q4
160
31.09M
95.12%
-3.10M
2024Q3
156
31.41M
96.35%
-1.62M
2024Q2
150
31.22M
97.59%
-974.84K
2024Q1
140
30.76M
96.24%
+4.98M
2023Q4
127
22.26M
93.52%
+3.25M
2023Q3
124
22.70M
95.37%
+3.35M
2023Q2
119
23.17M
97.35%
+3.81M
2023Q1
108
18.62M
78.36%
-609.71K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
10.69M
32.67%
--
--
Mar 31, 2025
Oxford Science Enterprises PLC
4.76M
14.53%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
2.68M
8.18%
+804.74K
+43.01%
Mar 31, 2025
Millennium Management LLC
1.03M
3.16%
+876.38K
+559.50%
Mar 31, 2025
Viking Global Investors LP
1.48M
4.53%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
1.35M
4.13%
+550.00K
+68.75%
Mar 31, 2025
Qatar Investment Authority
1.24M
3.8%
--
--
Sep 30, 2024
The Vanguard Group, Inc.
899.73K
2.75%
-12.94K
-1.42%
Mar 31, 2025
Laurion Capital Management LP
810.76K
2.48%
--
--
Mar 31, 2025
Woodline Partners LP
780.90K
2.39%
+780.90K
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
ProShares Ultra Nasdaq Biotechnology
0%
Proshares Ultra Russell 2000
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
ProShares UltraPro Russell2000
0%
iShares Micro-Cap ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
iShares Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
占比0%
Proshares Ultra Russell 2000
占比0%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0%
ProShares UltraPro Russell2000
占比0%
iShares Micro-Cap ETF
占比0%
Invesco Nasdaq Biotechnology ETF
占比0%
ProShares Hedge Replication ETF
占比0%
iShares Biotechnology ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
